CD36 and malaria: Friends or foes? A decade of data provides some answers

Trends in Parasitology

Volumn 30, Issue 9, 2014, Pages 436-444

  Cabrera, Ana ^a   Neculai, Dante ^b   Kain, Kevin C ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

CD36; Endothelial activation; Endothelial protein C receptor; PfEMP1; Scavenger receptors

Indexed keywords

ARTESUNATE; CD36 ANTIGEN; ENDOTHELIAL PROTEIN C RECEPTOR; PLACEBO; ROSIGLITAZONE;

CELL MEMBRANE; DISEASE SEVERITY; DRUG EFFICACY; ERYTHROCYTE; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HOST PARASITE INTERACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MALARIA; NONHUMAN; PARASITE; PARASITE ERYTHROCYTE; PATHOGENESIS; PHAGOCYTOSIS; PLASMODIUM FALCIPARUM; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE;

CD36; ENDOTHELIAL ACTIVATION; ENDOTHELIAL PROTEIN C RECEPTOR; PFEMP1; SCAVENGER RECEPTORS;

ANTIGENS, CD36; HOST-PARASITE INTERACTIONS; HUMANS; IMMUNITY, INNATE; MALARIA; PARASITOLOGY; PLASMODIUM;

EID: 84906936626     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2014.07.006     Document Type: Review

References (85)

1. Kwiatkowski D.P. How malaria has affected the human genome and what human genetics can teach us about malaria. Am. J. Hum. Genet. 2005, 77:171-192.
2. Allison A.C. The distribution of the sickle-cell trait in East Africa and elsewhere, and its apparent relationship to the incidence of subtertian malaria. Trans. R. Soc. Trop. Med. Hyg. 1954, 48:312-318.
3. Haldane J.B.S. Disease and evolution. La Ricerca Scientifica 1949, 19(Suppl.):68-76.
4. Scherf A., et al. Antigenic variation in Plasmodium falciparum. Annu. Rev. Microbiol. 2008, 62:445-470.
5. Canton J., et al. Scavenger receptors in homeostasis and immunity. Nat. Rev. Immunol. 2013, 13:621-634.
6. Fonager J., et al. Reduced CD36-dependent tissue sequestration of Plasmodium-infected erythrocytes is detrimental to malaria parasite growth in vivo. J. Exp. Med. 2012, 209:93-107.
7. Baranova I.N., et al. Role of human CD36 in bacterial recognition, phagocytosis, and pathogen-induced JNK-mediated signaling. J. Immunol. 2008, 181:7147-7156.
8. Patel S.N., et al. Disruption of CD36 impairs cytokine response to Plasmodium falciparum glycosylphosphatidylinositol and confers susceptibility to severe and fatal malaria in vivo. J. Immunol. 2007, 178:3954-3961.
9. Stuart L.M., et al. Response to Staphylococcus aureus requires CD36-mediated phagocytosis triggered by the COOH-terminal cytoplasmic domain. J. Cell. Biol. 2005, 170:477-485.
10. McGilvray I.D., et al. Nonopsonic monocyte/macrophage phagocytosis of Plasmodium falciparum-parasitized erythrocytes: a role for CD36 in malaria clearance. Blood 2000, 96:3231-3240.
11. Serghides L., et al. CD36 and malaria: friends or foes?. Trends Parasitol. 2003, 19:461-469.
12. Grau G.E., Craig A.G. Cerebral malaria pathogenesis: revisiting parasite and host contributions. Future Microbiol. 2012, 7:291-302.
13. Rowe J.A., et al. Adhesion of Plasmodium falciparum-infected erythrocytes to human cells: molecular mechanisms and therapeutic implications. Expert Rev. Mol. Med. 2009, 11:e16.
14. Cunnington A.J., et al. Stuck in a rut? Reconsidering the role of parasite sequestration in severe malaria syndromes. Trends Parasitol. 2013, 29:585-592.
15. Love-Gregory L., et al. Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. Hum. Mol. Genet. 2008, 17:1695-1704.
16. Laugerette F., et al. CD36 involvement in orosensory detection of dietary lipids, spontaneous fat preference, and digestive secretions. J. Clin. Invest. 2005, 115:3177-3184.
17. Leprête F., et al. A CD36 nonsense mutation associated with insulin resistance and familial type 2 diabetes. Hum. Mutat. 2004, 24:104.
18. Dawson D.W., et al. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 1997, 138:707-717.
19. Savill J., et al. Macrophage vitronectin receptor, CD36, and thrombospondin cooperate in recognition of neutrophils undergoing programmed cell death. Chest 1991, 99:6S-7S.
20. Asch A.S., et al. Isolation of the thrombospondin membrane receptor. J. Clin. Invest. 1987, 79:1054-1061.
21. Dondorp A.M., et al. Levamisole inhibits sequestration of infected red blood cells in patients with falciparum malaria. J. Infect. Dis. 2007, 196:460-466.
22. Silverstein R.L., et al. Mechanisms of cell signaling by the scavenger receptor CD36: implications in atherosclerosis and thrombosis. Trans. Am. Clin. Climatol. Assoc. 2010, 121:206-220.
23. Turner G.D., et al. An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am. J. Pathol. 1994, 145:1057-1069.
24. Ochola L.B., et al. Specific receptor usage in Plasmodium falciparum cytoadherence is associated with disease outcome. PLoS ONE 2011, 6:e14741.
25. Newbold C., et al. Receptor-specific adhesion and clinical disease in Plasmodium falciparum. Am. J. Trop. Med. Hyg. 1997, 57:389-398.
26. Warimwe G.M., et al. Plasmodium falciparum var gene expression is modified by host immunity. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:21801-21806.
27. Avril M., et al. DC8 DC13 var genes associated with severe malaria bind avidly to diverse endothelial cells. PLoS Pathog. 2013, 9:e1003430.
28. Lavstsen T., et al. Plasmodium falciparum erythrocyte membrane protein 1 domain cassettes 8, 13 are associated with severe malaria in children. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E1791-E1800.
29. Avril M., et al. A restricted subset of var genes mediates adherence of Plasmodium falciparum-infected erythrocytes to brain endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E1782-E1790.
30. Claessens A., et al. A subset of group A-like var genes encodes the malaria parasite ligands for binding to human brain endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E1772-E1781.
31. Turner L., et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature 2013, 498:502-505.
32. Gleeson E.M., et al. The endothelial cell protein C receptor: cell surface conductor of cytoprotective coagulation factor signaling. Cell. Mol. Life Sci. 2012, 69:717-726.
33. Moxon C.A., et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood 2013, 122:842-851.
34. Van der Poll T. The endothelial protein C receptor and malaria. Blood 2013, 122:624-625.
35. Aird W.C., et al. Plasmodium falciparum picks (on) EPCR. Blood 2014, 123:163-167.
36. Sailo L., et al. Disseminated intravascular coagulation in malaria: a case report. Niger. Med. J. 2014, 55:171-172.
37. Moxon C.A., et al. Dysregulation of coagulation in cerebral malaria. Mol. Biochem. Parasitol. 2009, 166:99-108.
38. Liechti M.E., et al. Plasmodium falciparum cerebral malaria complicated by disseminated intravascular coagulation and symmetrical peripheral gangrene: case report and review. Eur. J. Clin. Microbiol. Infect. Dis. 2003, 22:551-554.
39. Kim H., et al. Functional roles for C5a and C5aR but not C5L2 in the pathogenesis of human and experimental cerebral malaria. Infect. Immun. 2014, 82:371-379.
40. Conroy A.L., et al. Complement activation and the resulting placental vascular insufficiency drives fetal growth restriction associated with placental malaria. Cell. Host Microbe 2013, 13:215-226.
41. Patel S.N., et al. C5 deficiency and C5a or C5aR blockade protects against cerebral malaria. J. Exp. Med. 2008, 205:1133-1143.
42. Erdman L.K., et al. Combinations of host biomarkers predict mortality among Ugandan children with severe malaria: a retrospective case-control study. PLoS ONE 2011, 6:e17440.
43. Conroy A.L., et al. Angiopoietin-2 levels are associated with retinopathy and predict mortality in Malawian children with cerebral malaria: a retrospective case-control study. Crit. Care Med. 2012, 40:952-959.
44. Lovegrove F.E., et al. Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PLoS ONE 2009, 4:e4912.
45. Yeo T.W., et al. Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:17097-17102.
46. Cunnington A.J., et al. Piecing together the puzzle of severe malaria. Sci. Transl. Med. 2013, 5:211ps18.
47. Lovegrove F.E., et al. Parasite burden and CD36-mediated sequestration are determinants of acute lung injury in an experimental malaria model. PLoS Pathog. 2008, 4:e1000068.
48. Anidi I.U., et al. CD36 and Fyn kinase mediate malaria-induced lung endothelial barrier dysfunction in mice infected with Plasmodium berghei. PLoS ONE 2013, 8:e71010.
49. Bridges D.J., et al. Rapid activation of endothelial cells enables Plasmodium falciparum adhesion to platelet-decorated von Willebrand factor strings. Blood 2010, 115:1472-1474.
50. Wassmer S.C., et al. Platelets reorient Plasmodium falciparum-infected erythrocyte cytoadhesion to activated endothelial cells. J. Infect. Dis. 2004, 189:180-189.
51. Pain A., et al. Platelet-mediated clumping of Plasmodium falciparum-infected erythrocytes is a common adhesive phenotype and is associated with severe malaria. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:1805-1810.
52. Wassmer S.C., et al. Pathophysiology of cerebral malaria: role of host cells in the modulation of cytoadhesion. Ann. N. Y. Acad. Sci. 2003, 992:30-38.
53. Arman M., et al. A method for positive and negative selection of Plasmodium falciparum platelet-mediated clumping parasites and investigation of the role of CD36. PLoS ONE 2013, 8:e55453.
54. McMorran B.J., et al. Platelet factor 4 and Duffy antigen required for platelet killing of Plasmodium falciparum. Science 2012, 338:1348-1351.
55. Aggrey A.A., et al. Platelet induction of the acute-phase response is protective in murine experimental cerebral malaria. J. Immunol. 2013, 190:4685-4691.
56. McMorran B.J., et al. New insights into the protective power of platelets in malaria infection. Comm. Integr. Biol. 2013, 6:e23653.
57. World Health Organization Approaches to the diagnosis of malaria. New Perspectives Malaria Diagnosis (Report of the Joint WHO/USAID Informal Consultation 25-27 October 1999) 2000, 10-20. World Health Organization.
58. Patel S.N., et al. CD36 mediates the phagocytosis of Plasmodium falciparum-infected erythrocytes by rodent macrophages. J. Infect. Dis. 2004, 189:204-213.
59. Erdman L.K., et al. CD36 and TLR interactions in inflammation and phagocytosis: implications for malaria. J. Immunol. 2009, 183:6452-6459.
60. Hunt N.H., Grau G.E. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. Trends Immunol. 2003, 24:491-499.
61. Ayodo G., et al. Combining evidence of natural selection with association analysis increases power to detect malaria-resistance variants. Am. J. Hum. Genet. 2007, 81:234-242.
62. Pain A., et al. A non-sense mutation in Cd36 gene is associated with protection from severe malaria. Lancet 2001, 357:1502-1503.
63. Aitman T.J., et al. Malaria susceptibility and CD36 mutation. Nature 2000, 405:1015-1016.
64. Sinha S., et al. Variations in host genes encoding adhesion molecules and susceptibility to falciparum malaria in India. Malar. J. 2008, 7:250.
65. Omi K., et al. CD36 polymorphism is associated with protection from cerebral malaria. Am. J. Hum. Genet. 2003, 72:364-374.
66. Fry A.E., et al. Positive selection of a CD36 nonsense variant in sub-Saharan Africa, but no association with severe malaria phenotypes. Hum. Mol. Genet. 2009, 18:2683-2692.
67. Hawkes M., et al. Malaria exacerbates experimental mycobacterial infection in vitro and in vivo. Microbes Infect. 2010, 12:864-874.
68. Kyriacou H.M., et al. Differential var gene transcription in Plasmodium falciparum isolates from patients with cerebral malaria compared to hyperparasitaemia. Mol. Biochem. Parasitol. 2006, 150:211-218.
69. Conroy A.L., et al. Endothelium-based biomarkers are associated with cerebral malaria in Malawian children: a retrospective case-control study. PLoS ONE 2010, 5:e15291.
70. Kim H., et al. Endothelial activation and dysregulation in malaria: a potential target for novel therapeutics. Curr. Opin. Hematol. 2011, 18:177-185.
71. Serghides L., et al. Inhaled nitric oxide reduces endothelial activation and parasite accumulation in the brain, and enhances survival in experimental cerebral malaria. PLoS ONE 2011, 6:e27714.
72. Hawkes M., et al. Nitric oxide for the adjunctive treatment of severe malaria: hypothesis and rationale. Med. Hypotheses 2011, 77:437-444.
73. Moore K.J., et al. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat. Med. 2001, 7:41-47.
74. Serghides L., et al. PPARγ agonists improve survival and neurocognitive outcomes in experimental cerebral malaria and induce neuroprotective pathways in human malaria. PLoS Pathog. 2014, 10:e1003980.
75. Serghides L., et al. Rosiglitazone modulates the innate immune response to Plasmodium falciparum infection and improves outcome in experimental cerebral malaria. J. Infect. Dis. 2009, 199:1536-1545.
76. Serghides L., Kain K.C. Peroxisome proliferator-activated receptor gamma and retinoid X receptor agonists have minimal effects on the interaction of endothelial cells with Plasmodium falciparum-infected erythrocytes. Infect Immun. 2005, 73:1209-1213.
77. Serghides L., Kain K.C. Peroxisome proliferator-activated receptor gamma-retinoid X receptor agonists increase CD36-dependent phagocytosis of Plasmodium falciparum-parasitized erythrocytes and decrease malaria-induced TNF-alpha secretion by monocytes/macrophages. J. Immunol. 2001, 166:6742-6748.
78. Boggild A.K., et al. Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 2009, 49:841-849.
79. Kraemer S.M., Smith J.D. A family affair: var genes, PfEMP1 binding, and malaria disease. Curr. Opin. Microbiol. 2006, 9:374-380.
80. Janes J.H., et al. Investigating the host binding signature on the Plasmodium falciparum PfEMP1 protein family. PLoS Pathog. 2011, 7:e1002032.
81. Neculai D., et al. Structure of LIMP-2 provides functional insights with implications for SR-BI and CD36. Nature 2013, 504:172-176.
82. Hoosdally S.J., et al. The human scavenger receptor CD36: glycosylation status and its role in trafficking and function. J. Biol. Chem. 2009, 284:16277-16288.
83. Silverstein R.L., Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci. Signal. 2009, 2:re3.
84. Ho M., et al. Ectophosphorylation of CD36 regulates cytoadherence of Plasmodium falciparum to microvascular endothelium under flow conditions. Infect Immun. 2005, 73:8179-8187.
85. Bouwens E.A., et al. Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J. Thromb. Haemost. 2013, 11(Suppl. 1):242-253.